PowerShares DWA Healthcare Momentum Portfolio PTH 深 沪
等待开盘 11-05 09:30:00 美东时间
47.5912
-0.468
-0.97%
华盛通- 最 高48.1529
- 今 开47.547
- 成交量 5372股
- 最 低 47.547
- 昨 收 48.0596
- 总市值 1.27亿
- 52周最高 48.805
- 市盈率 静 --
- 换手率 0.20%
- 52周最低 33.5611
- 委 比 71.43%
- 总股本 266.00万
- 历史最高 64.6295
- 量 比 0.59
- 振 幅 1.26%
- 历史最低 6.9445
- 每 手 1
- 风险率 3.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Entera Bio Releases New Phase 2 Data At NAMS 2025 Showing That EB613, An Oral PTH[1-34] Therapy, Consistently Increased Bone Mineral Density In Both Early Postmenopausal Women And Those 10 Years Post-Menopause
Consistency of BMD gains presented at NAMS 2025 demonstrate EB613's efficacy in both young postmenopausal women and in women 10 years post-menopauseData further support EB613 potential as a first-in-class oral anabolic
10-23 20:58
Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum
Pelthos Therapeutics has launched the Moms Against Molluscum movement to unite families affected by molluscum contagiosum, a highly contagious skin infection impacting 16.7 million Americans, mostly children. The initiative aims to provide resources and support through MomsAgainstMolluscum.com, sharing personal stories and offering information on new treatments like ZELSUVMI™, a first-of-its-kind topical gel approved for at-home use. The campaign...
10-09 12:00
新股消息 | 麦科奥特冲刺港交所 核心产品MT1013处于III期临床试验
据港交所9月29日披露，陕西麦科奥特科技有限公司(简称：麦科奥特)向港交所主板提交上市申请书，建银国际、招商证券国际为其联席保荐人。
09-30 07:00
MBX surges 160% on mid-stage data for hypoparathyroidism drug canvuparatide
MBX Biosciences (NASDAQ:MBX) is up ~160% in Monday morning trading after posting phase 2 data on hypoparathyroidism candidate canvuparatide indicating it met its primary goal. In the 12-week randomize...
09-22 22:20
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.
09-18 23:51
重磅收购取得新进展！9100亿芯片巨头明起复牌 | 盘后公告精选
国产“芯片一哥”明起复牌，PCB概念股异动期间实控人减持30万股公司股份，这一机器人概念股控制权恐生变......
09-08 21:17
Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference
Pelthos Therapeutics Inc. announced that its CEO, Scott Plesha, and CFO, Frank Knuettel, will present at the Wells Fargo Healthcare Conference on September 3, 2025, at 1:30 p.m. ET. The presentation will be available via webcast on Pelthos' website, with an archive available for 90 days. Pelthos, a biopharmaceutical company, focuses on innovative therapeutic products, with its lead product, ZELSUVMI™, approved for molluscum contagiosum treatment.
09-02 12:00
Ascendis Pharma To Present New Data From Week 156 Of Phase 3 PaTHway Trial Demonstrating Safety And Efficacy Of Long-Term Treatment With TransCon PTH In Adults With Hypoparathyroidism, At ENDO 2025
Ascendis Pharma A/S (NASDAQ:ASND) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being held July 12-15, 2025, in San Francisco. Dr. Aliya Khan will present new data from
07-08 04:03
Why Is Channel Therapeutics Stock Surging On Friday?
Channel Therapeutics shares rise after announcing 10-for-1 reverse stock split and upcoming rebrand.
06-27 23:55
The Analyst Verdict: Septerna In The Eyes Of 4 Experts
4 analysts have shared their evaluations of Septerna (NASDAQ:SEPN) during the r...
06-23 20:02
